MPAL: Difference between revisions
From haematologyetc.co.uk
No edit summary |
No edit summary |
||
Line 13: | Line 13: | ||
<div class="mw-collapsible mw-collapsed" data-expandtext="Click for explanation" data-collapsetext="Hide explanation"> | <div class="mw-collapsible mw-collapsed" data-expandtext="Click for explanation" data-collapsetext="Hide explanation"> | ||
<div class="mw-collapsible-content"> | <div class="mw-collapsible-content"> | ||
<span style="font-size:80%; text-align:left;"></br>The assignment of myeloid lineage recognises MPO expression to be a defining marker of myeloid lineage. However MPO is expressed only by around 80% of AML cases. The assignment of myeloid lineage can therefore also be made if monocytic lineage can be established, requiring at least | <span style="font-size:80%; text-align:left;"></br>The assignment of myeloid lineage recognises MPO expression to be a defining marker of myeloid lineage. However MPO is expressed only by around 80% of AML cases. The assignment of myeloid lineage can therefore also be made if monocytic lineage can be established, requiring at least 2 of 5 possible lineage markers to be detected (although only 3 of these can be established by flow cytometry).</br> | ||
</span> | </span> | ||
</div></div></div> | </div></div></div> | ||
Line 20: | Line 20: | ||
|- | |- | ||
|colspan="1" style = "font-size:90%; color:black;" |'''[[MPO|Myeloperoxidase (MPO)]]''' | |colspan="1" style = "font-size:90%; color:black;" |'''[[MPO|Myeloperoxidase (MPO)]]''' | ||
|colspan="1" style = "font-size:90%;"|This marker alone is sufficient to establish myeloid lineage | |colspan="1" style = "font-size:90%;"|This marker alone is sufficient to establish myeloid lineage but be aware of the limitations: (1) intensity should be at least half of that of mature neutrophils in at least of proportion of cells measured by the same method, (2) there are circumstances where judgement is required (see notes). | ||
|- | |- | ||
|colspan="2" style = "font-size:90%; color:black; background:#ddeee1" |'''marker option 2''' | |colspan="2" style = "font-size:90%; color:black; background:#ddeee1" |'''marker option 2''' |
Revision as of 11:35, 9 November 2023
Assignment of category to ambiguous cases in acute leukaemia:
Final lineage requires integration of additional molecular features; assignments made by flow are therefore "provisional" pending full molecular assessment. Four categories may be assigned:
- My/B
- My/T**
- T/B
- Undiff
.
Requirements to assign myeloid lineage in MPAL
| |
---|---|
Marker option 1 | |
Myeloperoxidase (MPO) | This marker alone is sufficient to establish myeloid lineage but be aware of the limitations: (1) intensity should be at least half of that of mature neutrophils in at least of proportion of cells measured by the same method, (2) there are circumstances where judgement is required (see notes). |
marker option 2 | |
If MPO does not meet criteria for myeloid lineage, then myeloid lineage may still be assigned through demonstration of monocytic lineage. This can be assigned by the detection of at least two of the following features: By flow cytometry: CD11c, CD14, CD64; by other approaches: raised lysozyme in serum or urine or non-specific esterase in malignant cells (enzyme cytochemistry) |
.
Requirements to assign B-lymphoid lineage in MPAL
| |
---|---|
Marker option 1 | |
Required Strong expression of CD19 | To meet the definition of "strong" the expression intensity must exceed that of 50% of normal B lymphocytes |
In addition 1 of: CD10, CD22, or CD79a (surface or cytoplasmic) | If CD19 is strong then B-lineage can be assigned if there is at least ONE of these additional markers |
Marker option 2 | |
Required Weak expression of CD19 | To meet the definition of "weak" the expression intensity must be less than that of 50% of normal B lymphocytes |
In addition 2 of: CD10, CD22, or CD79a (surface or cytoplasmic) | If CD19 is weak then B-lineage can be assigned only if there are at least TWO of these additional markers |
.
Requirements to assign T-lymphoid lineage in MPAL
| |
---|---|
Marker requirement | |
Either CD3 surface or cytoplasm (strong) | To meet the definition of "strong" the expression intensity must exceed that of 50% of normal T lymphocytes |
Or CD3 by immunocytochemistry (strong) | For immunohistochemistry it is important a non-zeta chain reagent is used |